NCT01551147 - A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2013

Conditions

Asthma

Interventions

DRUG

ONO-6950

200 mg QD for 8 days

DRUG

Placebo

Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner

DRUG

Montelukast

10 mg Montelukast QD for 8 days

Trial Locations (5)

Vancouver Clinical Site 530, Vancouver

Calgary Clinical Site 540, Alberta

Hamilton Clinical Site 550, Ontario

Quebec Clinical Site 510, Québec

Saskatoon Clinical Site 520, Saskatoon